(p. A10) . . . , preliminary results on treatments with . . . sarilumab, marketed as Kevzara and made by Regeneron and Sanofi, indicate that it does not help patients who are hospitalized but not using ventilators.
. . .
The patients fell into two groups — “severe,” meaning they required oxygen but did not need a ventilator or so-called high flow oxygen, and “critical,” those who needed a ventilator, high flow oxygen or were in intensive care.
. . .
The results for the critically ill patients are not conclusive but there is a hint that such patients may be helped, so the study will continue with only critically ill patients. More than 600 have been enrolled. Results are expected in early June .
For the full story, see:
Gina Kolata. “Drug Shows Slim Promise For Critical Covid Cases.” The New York Times (Tuesday, April 28, 2020): A10.
(Note: ellipses, and bracketed year, added.)
(Note: the online version of the story has the date April 27, 2020, and has the title “Arthritis Drug Did Not Help Seriously Ill Covid Patients, Early Data Shows.”)